I Hate Dialysis Message Board
Dialysis Discussion => Dialysis: News Articles => Topic started by: Meinuk on September 21, 2011, 09:07:55 AM
-
http://www.nytimes.com/2011/09/17/health/17insider.html?_r=1&scp=1&sq=kidney%20drug&st=cse
I'm not going to post the whole article. In my opinion, essentially, it is about greed. My take on all of this is that the more that we see what is going on behind the scenes at these drug companies, we will find out how our health is nothing but a catalyst for people to make money...
Really? "The drug costs more than $23,000 a vial; Questcor, betting on its value, had raised the price from $1,650 a vial in 2007" really? From $1,650 to $23,000??? And these people sleep at night? Well, they do sleep at night on Duxiana Beds with Pratesi Sheets.
And we wonder why our insurance premiums are so high... (if our insurance would pay for the drug at all - a pity, research showed that it helped 9/11 people with "a certain type of nephrotic syndrom".)
From: Columbia Professor Is Linked to Insider Trading Case (Bolding my emphasis).
The study found that 9 of 11 of the patients with a certain type of nephrotic syndrome responded well to treatment. In doing so, the study has helped transform the drug, called H.P. Acthar Gel, from the status of an orphan to that of a potential blockbuster.
Questcor told investors this month that the expensive, injectable drug could have $1 billion sales for the niche condition Dr. Bomback studied. The drug costs more than $23,000 a vial; Questcor, betting on its value, had raised the price from $1,650 a vial in 2007. The drug is also sold for ultrarare infant spasms and select multiple sclerosis patients.
link to the study: http://www.dovepress.com/treatment-of-nephrotic-syndrome-with-adrenocorticotropic-hormone-acth--a6667